1. Home
  2. BEAT vs GBIO Comparison

BEAT vs GBIO Comparison

Compare BEAT & GBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BEAT
  • GBIO
  • Stock Information
  • Founded
  • BEAT 2015
  • GBIO 2016
  • Country
  • BEAT United States
  • GBIO United States
  • Employees
  • BEAT N/A
  • GBIO N/A
  • Industry
  • BEAT Retail: Computer Software & Peripheral Equipment
  • GBIO Biotechnology: Pharmaceutical Preparations
  • Sector
  • BEAT Technology
  • GBIO Health Care
  • Exchange
  • BEAT Nasdaq
  • GBIO Nasdaq
  • Market Cap
  • BEAT 74.1M
  • GBIO 64.8M
  • IPO Year
  • BEAT 2021
  • GBIO 2020
  • Fundamental
  • Price
  • BEAT $2.26
  • GBIO $0.78
  • Analyst Decision
  • BEAT Buy
  • GBIO Strong Buy
  • Analyst Count
  • BEAT 1
  • GBIO 2
  • Target Price
  • BEAT $8.00
  • GBIO $6.50
  • AVG Volume (30 Days)
  • BEAT 110.4K
  • GBIO 649.2K
  • Earning Date
  • BEAT 03-19-2025
  • GBIO 03-05-2025
  • Dividend Yield
  • BEAT N/A
  • GBIO N/A
  • EPS Growth
  • BEAT N/A
  • GBIO N/A
  • EPS
  • BEAT N/A
  • GBIO N/A
  • Revenue
  • BEAT N/A
  • GBIO $18,582,000.00
  • Revenue This Year
  • BEAT N/A
  • GBIO $212.74
  • Revenue Next Year
  • BEAT N/A
  • GBIO N/A
  • P/E Ratio
  • BEAT N/A
  • GBIO N/A
  • Revenue Growth
  • BEAT N/A
  • GBIO 514.08
  • 52 Week Low
  • BEAT $1.35
  • GBIO $0.72
  • 52 Week High
  • BEAT $3.48
  • GBIO $4.65
  • Technical
  • Relative Strength Index (RSI)
  • BEAT 47.78
  • GBIO 29.26
  • Support Level
  • BEAT $2.02
  • GBIO $0.72
  • Resistance Level
  • BEAT $2.44
  • GBIO $1.00
  • Average True Range (ATR)
  • BEAT 0.14
  • GBIO 0.07
  • MACD
  • BEAT 0.04
  • GBIO -0.00
  • Stochastic Oscillator
  • BEAT 50.00
  • GBIO 18.68

About BEAT Heartbeam Inc.

HeartBeam Inc is a medical technology company primarily focusing on developing and commercializing higher resolution ambulatory Electrocardiogram ("ECG") solutions that enable the detection and monitoring of cardiac disease outside a healthcare facility setting. The Company's ability to develop higher-resolution ECG solutions is achieved through the development of the Company's proprietary and patented Vector Electrocardiography ("VECG") technology platform. The Company has validated this technology and is seeking U.S. Food and Drug Administration ("FDA") clearance for its initial telehealth products.

About GBIO Generation Bio Co.

Generation Bio Co is a genetics medicine company that is focused on creating gene therapies to provide durable and redosable treatments for patients suffering from rare and untreated diseases. The company focuses on liver and retina-related diseases. It is developing two distinct and complementary platforms that It believes will enable highly differentiated therapeutic applications. Its first platform is a potent, highly selective ctLNP delivery system for nucleic acids, which is designed to avoid off-target clearance by the liver and spleen, enabling ctLNPs to persist in systemic circulation and allowing for highly selective and potent ligand-driven targeting to specific tissues and cell types. Its second platform is its novel iqDNA, which is an optimized variant of its ceDNA.

Share on Social Networks: